Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)


Researchers are trying to understand the effects of mesenchymal stem cells therapy in subjects with advance chronic obstructive pulmonary disease

Full Title of Study: “A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 16, 2021


  • Biological: Mesenchymal Stem Cells
    • 0.5- 2 million cells/kg, intravenously once

Arms, Groups and Cohorts

  • Experimental: Subjects with Advanced Chronic Obstructive Pulmonary Disease
    • Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events
    • Time Frame: One hour post completion of infusion
    • Number of subjects to tolerate IV infusion of Mesenchymal Stem Cells (MSC) without acute clinical or physiological deterioration

Participating in This Clinical Trial

Inclusion Criteria

  • Age range: 40 – 65 years
  • Gender: Male or female
  • Target disease or condition: Subjects with advance COPD
  • Subject must have a post-bronchodilator FEV1/FVC ratio of less than 0.7
  • Subject must have a post-bronchodilator FEV1percent predicted value between 20% and 49%.
  • Subject must have a total lung capacity (TLC) percent predicted of 80% or more
  • Subject must be an ex-smoker, with a cigarette smoking history of ≥ 10 pack-years.
  • Subject must have abstained from nicotine products for at least six months prior to enrollment in the study.
  • Subjects must score at least 2 in the modified Medical Research Council (mMRC)
  • Subjects must have had an exacerbation of COPD within the last 12 months prior to enrollment in the study. An acute exacerbation of COPD is defined as a respiratory event requiring the use of antibiotics or systemic steroids or both.
  • Informed consent form (ICF): Each patient will be required to sign an IRB approved ICF. Only subjects who have signed the ICF will be enrolled into the study. The ICF will include elements required by Mayo IRB and FDA in US 21CFR50.
  • Subject must have a calculated creatinine clearance of greater than 30 ml/min.
  • Subject must be available for all specified assessments at the study site through the completion of the study.
  • Subject must provide written ICF and authorization for use of and disclosure of PHI.
  • Subjects must have oxyhemoglobin saturation on room air at rest equal or greater than 88%.

Exclusion Criteria

  • Patients with clinically significant illness with manifestations of significant organ dysfunction which in the judgment of the PI or co-investigator would render the study subject unlikely to tolerate the MSC infusion or complete the study
  • Subject has been diagnosed with a pulmonary disease other than COPD (e.g. asthma, pulmonary fibrosis, sarcoidosis, pulmonary hypertension, bronchiolitis, interstitial lung disease)
  • Subject has been diagnosed with α1-Antitrypsin deficiency
  • Subject has a body mass index greater than 35 or less than 16
  • Subject has or has had an active infection requiring systemic antibiotics within 12 weeks on enrollment in the study
  • Subject has had exacerbation of COPD requiring hospitalization within 12 weeks of enrollment in the study.
  • Subject has initiated pulmonary rehabilitation within 12 weeks of enrollment in the study
  • Subject uses or used prednisone (or equivalent dose of another corticosteroid) within 12 weeks of enrollment in the study
  • Subject has evidence or history of malignancy
  • Subject has evidence or history of autoimmune disorders independent of COPD
  • Subject is pregnant or breast-feeding
  • Subject has a history of HIV, Hepatitis B and/or Hepatitis C
  • Subject has evidence of liver dysfunction manifested as alkaline phosphatase greater than 345 u/L, total bilirubin greater than 1.65 mg/dL, ALT greater than 275 units/L and/or AST great than 240 units/L.
  • Subject has evidence of significant cardiac dysfunction, e.g. acute myocardial infarction within 3 months of screening, patients with the diagnosis of unstable angina. Patients with the diagnosis of "Cor pulmonale", uncontrolled tachyarrhythmia or bradyarrhythmia, atrial fibrillation or atrial flutter, history of insertion of pacemaker or implantable cardioverter-defibrillator, patient with clinical diagnose of heart failure with preserved or reduced ejection fraction and patients with a history of congenital heart disease.
  • Subjects with pulmonary lobectomy or lung volume reduction surgery or lung transplantation.
  • Subjects with clinically significant bronchiectasis.
  • Subject received an experimental therapy (drug or biologic) for any indication within 12 months of the study enrollment
  • Subject is unable to complete all the testing required for the study
  • Subjects who are on immunosuppressive medications.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mayo Clinic
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jorge M Mallea, Principal Investigator – Mayo Clinic
  • Overall Official(s)
    • Jorge M Mallea, MD, Principal Investigator, Mayo Clinic
  • Overall Contact(s)
    • Carolyne Stevens, 904-953-3937,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.